20Sプロテアソーム:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC1056TDB)
◆英語タイトル:20s Proteasome - Pipeline Review, H2 2017
◆商品コード:GMDHC1056TDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年10月17日
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における20Sプロテアソームの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・20Sプロテアソームの概要
・20Sプロテアソーム治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・20Sプロテアソームパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・20Sプロテアソーム治療薬開発に取り組んでいる企業:企業別製品パイプライン
・20Sプロテアソーム治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

20s Proteasome – Pipeline Review, H2 2017

Summary

According to the recently published report ’20s Proteasome – Pipeline Review, H2 2017′; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

20s Proteasome – 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

The report ’20s Proteasome – Pipeline Review, H2 2017′ outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women’s Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Tuberculosis and Uterine Leiomyoma (Uterine Fibroids).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 20s Proteasome
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
20s Proteasome – Overview 6
20s Proteasome – Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 12
Products under Development by Universities/Institutes 16
20s Proteasome – Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
20s Proteasome – Companies Involved in Therapeutics Development 22
Amgen Inc 22
Celgene Corp 24
20s Proteasome – Drug Profiles 25
carfilzomib – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
marizomib – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
oprozomib – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit 20s Proteasome for Tuberculosis – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
VPE-001 – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
VPEA-002 – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
VPEA-004 – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
20s Proteasome – Dormant Products 50
20s Proteasome – Product Development Milestones 51
Featured News & Press Releases 51
Aug 30, 2017: FDA Accepts Amgen’s Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS (Carfilzomib) Label 51
Aug 30, 2017: Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma 51
Aug 23, 2017: Overall Survival Analysis From KYPROLIS Phase 3 Endeavor Trial Published In The Lancet Oncology 52
Aug 08, 2017: Scottish Medicines Consortium Accepts Amgen’s Multiple Myeloma Treatment, KYPROLIS (carfilzomib), in Combination with Dexamethasone, for use at First Relapse 53
Aug 07, 2017: Amgen’s Kyprolis accepted for use in NHS Scotland 54
Jul 24, 2017: Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune as Adjuvant Therapy in Patients with Glioblastoma 54
Jul 19, 2017: NICE approves more tolerable treatment for blood cancer 55
Jul 14, 2017: Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS (Carfilzomib) Label 55
Jul 12, 2017: Second Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 56
Jun 21, 2017: Amgen To Present New Data on KYPROLIS At 22nd Congress of the European Hematology Association 57
Jun 13, 2017: Amgen’s Multiple Myeloma Treatment, KYPROLIS (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse 57
May 18, 2017: ONO Receives Supplemental Manufacturing and Marketing Approval of KYPROLIS for Intravenous Injection 10 mg and 40 mg, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 58
Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 59
Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 60
Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15
Number of Products under Investigation by Universities/Institutes, H2 2017 16
Products under Investigation by Universities/Institutes, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by Amgen Inc, H2 2017 23
Pipeline by Celgene Corp, H2 2017 24
Dormant Projects, H2 2017 50

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21

【レポートのキーワード】

20Sプロテアソーム

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 20Sプロテアソーム:治療薬開発パイプライン分析(20s Proteasome - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆